Anticancer metal compounds in NCI's tumor-screening database: putative mode of action

被引:164
作者
Huang, RL
Wallqvist, A
Covell, DG [1 ]
机构
[1] NCI, Dev Therapeut Program, Screening Technol Branch, Lab Computat Technol, Frederick, MD 21702 USA
[2] NCI, Sci Appl Int Corp, NIH, Frederick, MD 21702 USA
关键词
data mining; NCI tumor screen; metal compounds; mechanism of action; drug discovery; cancer;
D O I
10.1016/j.bcp.2005.01.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clustering analysis of tumor cell cytotoxicity profiles for the National Cancer Institute (NCI)'s open compound repository has been used to catalog over 1100 metal or metalloid containing compounds with potential anticancer activity. The molecular features and corresponding reactivity of these compounds have been analyzed in terms of properties of their metals, their associated organic components (ligands) and their capacity to inhibit tumor cell growth. Cytotoxic responses are influenced by both the identity of the metal and the properties of its coordination ligand, with clear associations between structural similarities and cytotoxicity. Assignments of mechanisms of action (MOAs) for these compounds could be segregated into four broad response classes according to preference for binding to biological sulfhydryl groups, chelation, generation of reactive oxygen species (ROS), and production of lipophilic ions. Correlations between specific cytotoxic responses and differential gene expression profiles within the NCI's tumor cell panel serve as a validation for candidate biological targets and putative MOA classes. In addition, specific sensitivity toward subsets of metal containing agents has been found for certain tumor cell panels. Taken together, our results expand the knowledge base available for evaluating, designing and developing new metal-based anticancer drugs that may provide the basis for target-specific therapeutics. Published by Elsevier Inc.
引用
收藏
页码:1009 / 1039
页数:31
相关论文
共 161 条
  • [31] Anticancer titanium agents
    Caruso, F
    Rossi, M
    Pettinari, C
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (06) : 969 - 979
  • [32] Preparation and characterization of the rhenium silyl esters (eta(5)-C5Me5)(CO)(NO)ReC(O)OSiR3 (SiR3=SiMe2Ph, SiEt3)
    Cavanaugh, MD
    Tetrick, SM
    Masi, CJ
    Cutler, AR
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 1997, 538 (1-2) : 41 - 48
  • [33] Syntheses of ruthenium(II) quinonediimine complexes of cyclam and characterization of their DNA-binding activities and cytotoxicity
    Chan, HL
    Liu, HC
    Tzeng, BLC
    You, YSY
    Peng, SM
    Yang, MS
    Che, CM
    [J]. INORGANIC CHEMISTRY, 2002, 41 (12) : 3161 - 3171
  • [34] Non-platinum chemotherapeutic metallopharmaceuticals
    Clarke, MJ
    Zhu, FC
    Frasca, DR
    [J]. CHEMICAL REVIEWS, 1999, 99 (09) : 2511 - 2533
  • [35] Cisplatin: From DNA damage to cancer chemotherapy
    Cohen, SM
    Lippard, SJ
    [J]. PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 67, 2001, 67 : 93 - 130
  • [36] Collery P, 2000, ANTICANCER RES, V20, P955
  • [37] STRUCTURE-FUNCTION-RELATIONSHIPS FOR A NEW SERIES OF PYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONES ON RIBONUCLEOTIDE REDUCTASE-ACTIVITY AND TUMOR-CELL GROWTH IN CULTURE AND IN-VITRO
    CORY, JG
    CORY, AH
    RAPPA, G
    LORICO, A
    LIU, MC
    LIN, TS
    SARTORELLI, AC
    [J]. ADVANCES IN ENZYME REGULATION, VOL 35, 1995, 35 : 55 - 68
  • [38] COVELL DG, 2005, IN PRESS PROTEINS
  • [39] Mode of anti-fungal activity of 1,10-phenanthroline and its Cu(II), Mn(II) and Ag(I) complexes
    Coyle, B
    Kavanagh, K
    McCann, M
    Devereux, M
    Geraghty, M
    [J]. BIOMETALS, 2003, 16 (02) : 321 - 329
  • [40] CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x